Associate Director, Biostatistics Clinical Late Stage Revolution MedicinesAssociate Director, Biostatistics Clinical Late StageRedwood City, California$186,000–$233,000 / yearThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.
Director, Clinical Pharmacology Arcus Biosciences, Inc.Director, Clinical PharmacologyHayward, CARemote$245,000–$260,000 / yearAt Arcus, the Director, Clinical Pharmacology (CP) functions as the Clinical Pharmacology (CP) team representative at the project teams for small molecule and biotherapeutics in Phase 1-3 of clinical development and is responsible for supporting all clinical pharmacology-related activities. This includes design and execution of clinical pharmacology studies, design of clinical pharmacology portion of other clinical studies, hands-on analysis and reporting of data, and communication of data and analysis reports in regulatory documents and meetings.
Associate Director, Clinical Data Management Revolution MedicinesAssociate Director, Clinical Data ManagementRedwood City, California$186,000–$233,000 / yearThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Provides CDM oversight of outsourced and partner-resourced clinical trials including scoping trials, project management, relationship management, approval of deliverables, and coordination of internal reviewers.
Associate Director, Clinical Quality Assurance Revolution MedicinesAssociate Director, Clinical Quality AssuranceRedwood City, California$186,000–$233,000 / yearThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.
Associate Director, Clinical Operations Compliance & Training Revolution MedicinesAssociate Director, Clinical Operations Compliance & TrainingRedwood City, California$186,000–$233,000 / yearThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies.
Director, Clinical Data Management Revolution MedicinesDirector, Clinical Data ManagementRedwood City, CaliforniaThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Provides CDM oversight of outsourced and partner-resourced clinical trials including scoping trials, project management, relationship management, approval of deliverables, and coordination of internal reviewers.
Associate Director, Clinical Quality Assurance Revolution Medicines IncAssociate Director, Clinical Quality AssuranceRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.
Senior Director, Clinical Data Management Revolution Medicines IncSenior Director, Clinical Data ManagementRedwood City, CA$244,000–$305,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The Opportunity: The Senior Director of Clinical Data Management provides high-level leadership for data management functions within clinical research, focusing on strategic development, operational execution, and regulatory compliance to ensure data integrity for clinical trials.
Director, Clinical Pharmacology Arcus Biosciences IncDirector, Clinical PharmacologyBrisbane, CARemote$245,000–$260,000 / yearAt Arcus, the Director, Clinical Pharmacology (CP) functions as the Clinical Pharmacology (CP) team representative at the project teams for small molecule and biotherapeutics in Phase 1-3 of clinical development and is responsible for supporting all clinical pharmacology-related activities. This includes design and execution of clinical pharmacology studies, design of clinical pharmacology portion of other clinical studies, hands-on analysis and reporting of data, and communication of data and analysis reports in regulatory documents and meetings.
Senior Clinical Operations Asset Director (Immunology, Neurology, Ophthalmology, and CVRM) Genentech IncSenior Clinical Operations Asset Director (Immunology, Neurology, Ophthalmology, and CVRM)South San Francisco, CA$215,000–$399,400 / yearThe Opportunity: As a Senior Clinical Operations Asset Director, you will provide strategic leadership across one or more development assets in Immunology, Neurology, Ophthalmology, and/or CVRM (Cardiovascular, Renal & Metabolism) while helping shape disease area strategy and the future of Clinical Operations. Our team provides strategic operational leadership that shapes development plans, drives execution excellence, and enables high-quality, efficient clinical trials.
Director, Clinical Data Management Revolution Medicines IncDirector, Clinical Data ManagementRedwood City, CA$211,000–$264,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Provides CDM oversight of outsourced and partner-resourced clinical trials including scoping trials, project management, relationship management, approval of deliverables, and coordination of internal reviewers.
Associate Director, Clinical Operations Compliance & Training Revolution Medicines IncAssociate Director, Clinical Operations Compliance & TrainingRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The company's R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies.
Senior Clinical Operations Asset Director (Oncology) Genentech IncSenior Clinical Operations Asset Director (Oncology)South San Francisco, CA$215,000–$399,400 / yearThe Opportunity: As a Senior Clinical Operations Asset Director, you will provide strategic leadership across one or more development assets spanning solid tumors and hematologic malignancies, helping shape Disease Area strategy and the future of Clinical Operations. Our team provides strategic operational leadership that shapes development plans, drives execution excellence, and enables high-quality, efficient clinical trials.
Associate Director, Clinical Biomarker Development Revolution Medicines IncAssociate Director, Clinical Biomarker DevelopmentRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The Opportunity: The Associate Director in Clinical Biomarker Development team, within Translational Medicine will play a key role in the design, execution, and interpretation of clinical biomarker strategies across Revolution Medicine's oncology pipeline.
Associate Director, Clinical Data Management Revolution Medicines IncAssociate Director, Clinical Data ManagementRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Provides CDM oversight of outsourced and partner-resourced clinical trials including scoping trials, project management, relationship management, approval of deliverables, and coordination of internal reviewers.
Associate Director, Biostatistics Clinical Late Stage Revolution Medicines IncAssociate Director, Biostatistics Clinical Late StageRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.
Senior Director, Clinical Science Ideaya Biosciences IncSenior Director, Clinical ScienceSouth San Francisco, CA$276,000–$341,000 / yearIn addition to study level activities, the Director/Senior Director will participate in program level activities including authoring/reviewing safety and efficacy summaries, clinical overviews, investigator brochures, risk management plans, periodic safety updates and clinical sections of product labels. Non-Solicitation Policy and Notice to Agencies and Recruiters: IDEAYA's Non-Solicitation Policy strictly prohibits agencies and recruiters from any contact and communication with IDEAYA employees, managers, and leaders to submit unsolicited candidate resumes and/or to solicit business partnerships.
Associate Director, Clinical Data Management Summit Therapeutics IncAssociate Director, Clinical Data ManagementPalo Alto, CA$174,000–$204,000 / yearLeads, designs and/or oversees eCRF design, eCRF specifications, eCRF completion guidelines, annotated CRFs, User Acceptance Testing, query logic, edit checks, data query resolution, SAE reconciliation between clinical and pharmacovigilance databases, vendor data reconciliation & cleaning, data migration and database closeout for clinical trials. Additionally, the position will manage data management staff, Contract Research Organizations (CROs) and service providers'' activities in overseeing the data management process life cycle in coordination with internal Biostatistics, Clinical, and Regulatory teams to ensure the accurate, efficient, and complete data collection for clinical trials.
Director, Clinical Business Operations Maze Therapeutics IncDirector, Clinical Business OperationsSouth San Francisco, CA$222,000–$271,000 / yearIn partnership with the Head of Clinical Operations, Oversight Directors, Study Leads, and Clinical Development functional leaders, you will oversee study and program budgets, financial forecasting, vendor financial management, and clinical business operations across the development portfolio. This role requires a highly collaborative professional who enjoys solving complex operational challenges and working across Clinical Operations, Safety, Biometrics, Finance, Procurement, Legal, and external partners to support operational effectiveness and organizational success.
Associate Director, Clinical Supply Planning Cytokinetics, IncorporatedAssociate Director, Clinical Supply PlanningSouth San Francisco, CA$195,390–$227,955 / yearThe Associate Director, Clinical Supply Chain, will develop and formulate supply chain strategies, meet project deliverables, solve business problems and drive improvements within Global Clinical Supply Chain (GCSC), as well as the Cytokinetics enterprise. Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction.